Pentavalent antimonial
PreclinicalSmall molecule
Pentavalent antimonial is one of 17 small molecule programs targeting Visceral Leishmaniasis. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
25 competitors in Visceral Leishmaniasis
#DrugCompanyPhaseTrials
1Amphotericin B Deoxycholate
Merck & Co.Approved
Ambisome
GileadApproved
Impavido
KKnight Therapeutics (USA) Inc
Phase 3
Abelcet
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Liposomal Lurtotecan
GileadPhase 3
Paromomycin Sulfate
PPATH
Approved
Meglumine Antimoniate
UUniversity of Brasilia
Approved
Pentamidine
OOncozyme Pharma Inc.
Phase 3
Paromomycin
DDrugs for Neglected Diseases
Phase 3
Sodium Stibogluconate
DDrugs for Neglected Diseases
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Pentavalent antimonial. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details